Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. ARCT has been the ...

Early crew members of the voyaging canoe Hokulea have gathered in Hawaii to celebrate the vessel's 50th birthday.

A canoe launched half a century ago helped turn Hawaiian culture from a source of shame to one of pride, reviving the skill ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $58.25, a high estimate of $63.00, ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $30 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European ...

BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive COVID-19 vaccine approval in Europe was reassuring for a ...

“KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This ...

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $ ...

Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics (NASDAQ:ARCT), expressing a variety of opinions spanning from bullish to bearish. The table below ...